- Home
- FKWL vs CVM Comparison
FKWL vs CVM Comparison
Compare FKWL & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FKWL | CVM |
|---|---|---|
| Founded | 1981 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 30.1M |
| IPO Year | 1997 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FKWL | CVM |
|---|---|---|
| Price | $2.37 | $1.65 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | 18.2K | ★ 212.2K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.10% | N/A |
| EPS Growth | ★ 94.12 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $46,086,901.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 49.65 | ★ 65.45 |
| 52 Week Low | $2.21 | $0.89 |
| 52 Week High | $5.48 | $13.48 |
Technical Indicators
Market Signals| Indicator | FKWL | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 62.89 |
| Support Level | $2.25 | $0.98 |
| Resistance Level | $3.79 | $1.80 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 75.47 | 78.75 |
Price Performance
Historical ComparisonAbout FKWL Franklin Wireless Corp.
Franklin Wireless Corp is a provider of wireless solutions, including mobile hotspots, routers, and modems, as well as hardware and software products that support machine-to-machine (M2M) applications and the Internet of Things (IoT). Its M2M and IoT solutions include embedded modules, modems, and gateways built to deliver reliable always-on connectivity supporting a spectrum of applications. These products are designed to solve wireless connectivity challenges in a range of vertical markets, including video surveillance, digital signage, home security, oil and gas exploration, kiosks, fleet management, smart grid, vehicle diagnostics, and telematics.
About CVM Cel-Sci Corporation
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.